Insider selling and profit-taking drive RXRX to near 52-week lows
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Revenue | $58.84M | $43.88M | $39.68M | $10.00M | $3.41M | $1.71M |
| Cost of Revenue | $45.24M | $42.59M | $48.27M | N/A | N/A | $45.81M |
| Gross Profit | $13.60M | $1.29M | $-8.59M | $10.00M | $3.41M | $-44.10M |
| Gross Margin | 23.12% | 2.94% | -21.66% | 100.00% | 100.00% | -2577.32% |
| Operating Expenses | $492.61M | $351.35M | $237.13M | $192.78M | $88.03M | $18.34M |
| Operating Income | $-479.00M | $-350.06M | $-245.73M | $-182.78M | $-84.61M | $-62.44M |
| Operating Margin | -814.09% | -797.84% | -619.26% | -1827.75% | -2479.20% | -3649.39% |
| Net Income | $-463.66M | $-328.07M | $-239.48M | $-186.48M | $-87.01M | $-62.52M |
| Net Margin | -788.02% | -747.71% | -603.50% | -1864.79% | -2549.25% | -3654.30% |
| EPS (Basic) | $-1.69 | $-1.58 | $-1.36 | $-1.05 | $-0.52 | $-0.37 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A |